KDventures AB (2I9)

Overview

Karolinska Development AB (publ) is a distinguished venture capital firm founded in 2003 with its headquarters situated in Stockholm, Sweden. This firm is dedicated to nurturing innovation within the realm of life sciences by providing financial investments and strategic support to promising early-stage, seed stage, and growth capital ventures. It primarily targets the pharmaceutical research and development, medical research, healthcare technology, and biotechnology sectors among others within the life science domain. Although its focus is predominantly on the Nordic region, covering countries such as Sweden, Iceland, Norway, Finland, and Denmark, the firm's vision extends to generating global impacts through its portfolio companies. Acting often as a lead investor but also considering co-investments, Karolinska Development AB ambitiously aims to invest in up to five projects annually, demonstrating its commitment to fostering breakthrough scientific advancements and technologies.

Products and Services

• Pharmaceutical Research and Development:

  Investment in companies involved in the groundbreaking development of pharmaceuticals, focusing on innovative drug discovery and development processes. These ventures seek to address unmet medical needs, aiming to significantly improve healthcare outcomes.

• Medical Research:

  Support for enterprises conducting advanced medical research, particularly those pioneering novel medical procedures or technologies that can lead to significant advancements in patient care and treatment modalities.

• Healthcare Technology:

  Funding for the development of cutting-edge healthcare technologies, including digital health solutions, that aim to enhance the efficiency and effectiveness of healthcare delivery, thereby improving patient outcomes.

• Gene Research and Development:

  Backing companies at the forefront of gene research and therapy development. This includes investments in genetic engineering, gene therapy, and other genomic innovations, reflecting the firm’s commitment to supporting the future of personalized medicine.

• Drug Delivery Technologies:

  Investment in new and innovative technologies for drug delivery systems that aim to optimize the efficacy and safety of pharmaceuticals, enhancing patient compliance and improving therapeutic outcomes.

• Biotechnology:

  Supporting biotechnology companies focusing on the application of biological systems and living organisms in developing products that may have various applications in industries including pharmaceuticals, agriculture, and environmental science.

• Life Science Tools and Services:

  Funding businesses that provide essential tools, technologies, and services which support the life sciences sector, including research tools, diagnostic solutions, and other support services critical for scientific breakthroughs.